Advertisement

help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schnell, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schnell, F. M.
The Oncologist, Vol. 8, No. 2, 187–198, April 2003
© 2003 AlphaMed Press


ORIGINAL PAPER
Symptom Management

Chemotherapy-Induced Nausea and Vomiting: The Importance of Acute Antiemetic Control

Frederick M. Schnell

Central Georgia Hematology and Oncology Associates, Macon, Georgia, USA

Correspondence: Frederick M. Schnell, M.D., F.A.C.P., Central Georgia Hematology and Oncology Associates, 682 Hemlock Street, Suite 100, Macon, Georgia 31201, USA. Telephone: 478-743-7068; Fax: 478-741-1354; e-mail: fmschnell{at}aol.com

Nausea and vomiting are two of the most feared side effects of cancer chemotherapy and radiotherapy. Chemotherapy-induced nausea and vomiting can be broadly categorized as acute (occurring within 24 hours of therapy), delayed (persisting for 6–7 days after therapy), or anticipatory (occurring prior to chemotherapy administration). Breakthrough and refractory nausea and vomiting describe the symptoms of uncontrolled emesis. Evidence suggests that good control of nausea and vomiting during the acute period correlates with the control of delayed emesis. Conversely, protection failure during the first 24 hours has a high predictive value for delayed emesis in the same cycle.

The 5-HT3-receptor antagonists, regarded as the ‘gold standard’ in antiemetic therapy, are the first-line treatment for moderately and highly emetogenic chemotherapy and radiotherapy regimens in adults and children. Evidence suggests that the 5-HT3-receptor antagonists administered in combination with corticosteroids afford the best protection from symptoms of acute emesis and, by extrapolation, the most effective prevention of delayed emesis.

Antiemetic therapeutic guidelines stress that the goal of therapy is to prevent cytostatic-induced nausea and vomiting. Therefore, the prophylactic use of the most effective antiemetic regimen—taking into consideration the emetogenicity of the chemotherapy and individual patient characteristics—must be adhered to in order to prevent acute, delayed, and anticipatory nausea and vomiting.

Key Words. Chemotherapy • Nausea • Vomiting • 5-HT3-receptor antagonists




This article has been cited by other articles:


Home page
JCOHome page
J. Herrstedt, W. Apornwirat, A. Shaharyar, Z. Aziz, F. Roila, S. Van Belle, M. W. Russo, J. Levin, S. Ranganathan, M. Guckert, et al.
Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
J. Clin. Oncol., November 10, 2009; 27(32): 5363 - 5369.
[Abstract] [Full Text] [PDF]


Home page
J Oncol Pharm PractHome page
M. Hamadani, L. Chaudhary, F. T. Awan, J. K. Khan, K. Kojouri, H. Ozer, and A. Tfayli
Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Journal of Oncology Pharmacy Practice, June 1, 2007; 13(2): 69 - 75.
[Abstract] [PDF]


Home page
Ann OncolHome page
S. Grunberg
Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis
Ann. Onc., February 1, 2007; 18(2): 233 - 240.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
A. Shah, T. DeGroot, and G. Apseloff
Pharmacokinetic evaluation and safety profile of a 15-minute versus 30-second infusion of palonosetron in healthy subjects.
J. Clin. Pharmacol., October 1, 2006; 46(10): 1139 - 1145.
[Abstract] [Full Text] [PDF]


Home page
DTBHome page
5HT3-receptor antagonists as antiemetics in cancer
DTB, August 1, 2005; 43(8): 57 - 62.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
M. S. Aapro, C.-H. Kohne, H. J. Cohen, and M. Extermann
Never Too Old? Age Should Not Be a Barrier to Enrollment in Cancer Clinical Trials
Oncologist, March 1, 2005; 10(3): 198 - 204.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2003 by AlphaMed Press.
Advertisement